ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease. The company currently has laboratory-based immunoassays available to measure the active forms of Neutrophil Elastase, Proteinase 3, Cathepsin G and Plasmin. NEATstik®, a rapid test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.
A range of other laboratory-based immunoassays and point-of-care tests designed for routine monitoring of chronic diseases are in development. ProAxsis also offers a highly experienced team who can provide clinical trial support services in regard to the specific measurement of active proteases and other inflammatory biomarkers within clinical samples.
ProAxsis offers measurement of a range of active protease biomarkers, including:
Our experts provide high quality clinical laboratory studies to investigate protease biomarkers of disease, to include activity profiling of samples and target validation.
ProAxsis can also offer a full range of analytical services for the measurement of other inflammatory mediators and differential cell counts, consulting and data management services within:
ProAxsis is able to support the development of bespoke assays for any protease target.
ProAxsis Limited has not received any reviews.
ProAxsis Limited has not received any endorsements.